GSC
TOVX icon

Ground Swell Capital’s Theriva Biologics TOVX Stock Holding History

Ground Swell Capital’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.83K Buy
+35,292
New +$10.5K 0.01% 124
2014
Q3 		– Hold
0
– -$1K – 2763
2014
Q2 		– Hold
0
– – – 1787

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Ground Swell Capital's TOVX Position: Q2 2026 in Review

Ground Swell Capital opened a new position in Theriva Biologics (TOVX) in Q2 2026: 35,292 shares worth $8.83K. The stake represents 0.01% of the portfolio and ranks #124 among its holdings.

26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Ground Swell Capital held 35,292 shares of Theriva Biologics worth $8.83K as of Q2 2026.
  • Theriva Biologics was a new Ground Swell Capital position in Q2 2026.
  • Theriva Biologics made up 0.01% of Ground Swell Capital's portfolio in Q2 2026, its #124 holding.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.